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Abstract 
The following case study shows a 59-year-old man on biologic therapy who visited his primary 
care provider for an upper respiratory illness. He was treated with symptomatic management 
with very close follow up by his primary care provider.  Recommendations for the primary care 
provider on the treatment of the acutely ill patient on biologic therapy are outlined as they related 
to the case. Biologic therapy is used to treat inflammatory conditions thought to be caused by 
inappropriate immune response. When on biologic therapy, however, a patient may have a 
decreased immune system to combat infectious agents. Articles related to increased risk of 
infections, guidelines for withholding biologics during active infection, and immunization 
considerations were reviewed. It was found that the decrease in immune activity caused by 
biologic therapy puts patients at increased risk for infection. Biologic treatment should be 
withheld during active infection, and patients on biologic therapy require close monitoring for 
worsening of acute respiratory symptoms. Specific vaccination recommendations where found, 
with live vaccinations being contraindicated during active treatment with biologics.  
Keywords: biologic therapy, immune response, vaccination  
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The Acutely Ill Patient on Biologics; What Primary Care Should Know 
Biologic response modifiers, or biologics, are a class of prescription medications that 
target immune system proteins to block the inflammatory response. Biologics are classified by 
the type of protein that they inhibit; tumor necrosis factor, B cells, T cells, or interleukins 
(Bombardier, 2012). These inflammatory blockers are useful in the treatment of many 
autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, 
irritable bowel syndrome, and juvenile arthritis. Often, biologics are not first line treatment 
options, but instead are reserved for use when other treatments have failed and are generally only 
prescribed by specialists (Saag et al., 2008). Although primary care providers may not be 
prescribing biologics to their patients, it is important to understand their immune-suppressing 
effects so that safe and effective treatment plans can be made in the primary care setting.  
The primary care provider may see patients who are currently on biologic therapies 
prescribed by a specialist for unrelated complaints. The following case will highlight such an 
instance where a patient is seeking primary care for an upper respiratory illness while on a 
biologic for rheumatoid arthritis. The case and following discussion of literature will demonstrate 
factors that the primary provider should consider in the treatment of the acutely ill patient that is 
on a biologic.  
Case Report 
 A 59-year-old Caucasian man presented to clinic with a five-day history of fever, chills, 
body aches, cough, and rhinorrhea. These symptoms had a very sudden onset, stating that he 
went to work in the morning feeling fine, and then had to leave work early due to sudden fatigue. 
Aches where described as generalized muscle aching and weakness, cough was non-productive 
and not worse during the night or when recumbent. He did not have any associated shortness of 
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breath or chest pains. Rhinorrhea was described as “clear and dripping”. He had tried over the 
counter cough drops and non-steroidal anti-inflammatory medications for pain relief and fever 
reduction with some improvement in symptoms.  He had multiple sick contacts in his office at 
work who exhibited the same symptoms. He had received the annual flu vaccination, but not the 
pneumococcal vaccination, and had no recent travel history. 
 Pertinent medical history would include diagnosis of rheumatoid arthritis for which he 
was managed by a Rheumatologist and was taking adalimumab subcutaneous injections and 
methotrexate. Also, he carries a diagnosis of essential hypertension for which he was taking an 
angiotensin converting enzyme inhibitor. He is a non-smoker with no known allergies, and lives 
in a house with his wife.  
 On physical exam vitals were noted as a blood pressures of 142/90, respiratory rate of 30, 
heart rate of 90, oxygen saturation level of 98%, and oral temperature of 102.4 degrees 
Fahrenheit. Generally, he did not appear in acute distress and was well groomed. Much of the 
exam was unremarkable, with lung sounds clear bilaterally without crackles or wheezes, heart 
with normal rate and rhythm, and negative for any joint swelling or tenderness. Only pertinent 
positives found were on the ear, nose, and throat exam was clear rhinorrhea from bilateral nares.  
 Based on physical exam and history of presenting illness it was concluded that this 
patient likely had a viral upper respiratory illness. Differential diagnoses would include acute 
bronchitis, pneumonia, influenza, or acute coryza. Given the unremarkable physical examination 
and five-day duration of symptoms a viral cause was thought to be most likely. No further lab 
work or diagnostics were performed, and symptomatic care was recommended. Testing for 
influenza was considered but deferred as the patient was past the recommended three-day 
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window for antiviral medication administration, therefore the treatment plan would not deviate 
from symptomatic care with a positive result of an influenza test.  
Symptomatic care education was provided and included the use of over the counter non-
steroidal anti-inflammatory agents and acetaminophen for fever reduction, over the counter 
cough suppressant at bedtime, and increase in fluid intake. Given the patient’s current use of the 
biologic therapies adalimumab and methotrexate he was instructed to return to clinic if 
symptoms did not improve in two to three days as he is at increased risk for developing 
infections due to his drug-induced immunocompromised state. If symptoms persisted further, 
workup would be indicated to rule out a bacterial infection. During the closure of the visit the 
patient questioned if he should continue to take his adalimumab while he is not feeling well. He 
was advised to reach out to his Rheumatologist for guidance.   
Literature Review 
 Patients on biologic therapy with acute illness, such as the individual in the above case, 
require special considerations when being treated in primary care. The use of a biologic 
suppresses the natural immune response, and therefore puts a patient at increased risk for 
development of infection and reduces the ability of the body to combat the infection effectively 
(Le Saux, 2012). The patient also may require closer follow-up and careful consideration of 
opportunistic infection as opposed to general community acquired bacteria (Bryant & Baddley, 
2016). It also may be necessary to discontinue use of the biologic while an active infection is 
occurring (Saag et al., 2008). Additionally, the primary care provider must consider the immune-
suppressing effects of biologics when recommending and giving vaccinations.  
 Biologic use suppresses the natural immune response by inhibiting tumor necrosis factor 
and the T-cell mediated responses that are responsible for the inflammatory cascade that kills or 
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preserves dormancy of pathogens (Le Saux, 2012). This is helpful to reduce the inflammatory 
effects of some diseases, but it is non-specific, meaning all inflammatory responses are reduced, 
including the response to an external pathogen that may cause illness. Those on biologics have 
an increased risk of developing infections, with infections of the upper respiratory tract being the 
most common (Menter et al., 2008).  
Individuals on biologics are also at increased risk for more serious opportunistic 
infections such as mycobacteria infection, tuberculosis, herpes zoster, pneumocystis, and 
histoplasmosis (Bryant & Baddley, 2016). Based on a Cochrane review of current literature 
related to adverse effects of biologic therapy, the actual risk of developing a serious infection or 
reactivating latent tuberculosis while on biologic therapy is relatively low. The review included 
160 randomized control trials which included almost 50,000 total participants, and included 
studies that examined the effects of biologics on the risks of developing serious infections, 
tuberculosis reactivation, and development of lymphomas and other malignancies. Overall, the 
review found that biologics where associated with statistically significant risk increase for 
development of serious infections and reactivation of latent tuberculosis. Serious infection risk, 
however, was overall relatively low, but did showed that 35 biologic-treated individuals out of 
1000 experienced a serious infection compared to 26 out of 1000 individuals on the placebo. 
Tuberculosis infections were also relatively uncommon, with 20 biologic-treated individuals out 
of 10,000 developing or reactivating tuberculosis compared to 4 out of 10,000 in the placebo 
group (Singh et al., 2011).   
Although the increased risk of opportunistic infection is relatively low, it would be 
prudent for the primary care provider to include such conditions in the differential diagnosis for 
the patient presenting with acute illness, particularly a respiratory illness. For example, in a 
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community-acquired pneumonia the typical host with a normal immune system likely would 
have a Pneumococcus infection, whereas the immunocompromised host may have a more 
atypical cause such as Aspergillus or mycobacterium. In this instance, the patient may require 
different, and perhaps more intensive antibiotic treatment and input from a specialist (Rali, Veer, 
Gupta, Singh, & Bhanot, 2016). 
 Much of the literature focused on serious complications and infections related to biologic 
use. In the literature review, there were no pertinent articles found related to common infections 
seen in primary care and the use of biologics, or for common infections in the immune-
compromised host. Several general treatment recommendations, however, where found that 
indicate that immunocompromised patients should be monitored more carefully for infection due 
to their increase susceptibility and decreased ability to fight infections. Kopylov and Afif (2014) 
recommend identifying and treating infections early in the infectious process in the individual on 
biologic therapy, and that the infection treatment takes precedent over the biologic therapy 
continuation. This sentiment is echoed by Pagalilauan and Limaye (2013) in that primary care 
providers need to be increasingly aware of the immunosuppressed patient and that they may be 
co-managing with a specialist, as the use of immune-suppressant therapy increases. Often the 
immunocompromised patient will seek out primary care for common complaints such as fever, 
new onset of cough, and gastrointestinal disturbances, which have the possibility of developing 
into a serious infection. Additionally, the signs of infection may be more subtle with 
immunosuppression, so the threshold for use of diagnostic labs, imagining, and treatment may be 
lower for this type of patient (Pagalilauan & Limaye, 2013).  
 Influenza is a common cause of infection in the immunosuppressed individual, and like 
the patient outlined in the case study above, can cause upper respiratory symptoms. In the 
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individual using a biologic, which suppresses the immune response, there may be an increased 
risk of secondary complications related to the viral influenza infection, such as viral or bacterial 
pneumonia (Weigt, Gregson, Deng, Lynch, & Belpe- Rio, 2011). This may prompt the primary 
care provider to follow up with the patient closely to ensure that the viral influenza does not 
cause a secondary infection, which would need to be treated promptly. The case study above 
outlines the close follow-up the primary provider suggested, with a return visit necessary if no 
improvement in two days.  
 The patient in this case also had a very prudent question regarding when he should hold 
his biologic medications. As biologics reduce the immune response, they may allow for 
infectious processes to continue and grow within the body. The decision to hold or stop biologic 
therapy generally would be overseen by the specialist prescribing the medication as they have 
more knowledge of the patient’s therapy and plan of care in relation to the biologic (Saag et al., 
2008). The primary care provider, however, should be aware of the general guidelines for 
indications to hold or discontinue a biologic in the setting of an acute illness.  
 The American College of Rheumatology issues guidelines for treatment with biologics, 
and Saag et al. (2008) stated that biologic therapy should not be initiated, used, or resumed while 
an active bacterial infection is present that requires the use of antibiotics. It also should not be 
used during active tuberculosis infection, herpes zoster infection, or in the presence of non-
healing infected skin ulcers. This guideline also suggested that biologics should not be used 
during a severe upper respiratory infection that is viral or bacterial, but the parameters for what 
constitutes a severe infection are not outlined. Specific classes of biologics (anti-tumor necrosis 
factor agents, T lymphocyte blockers, and rituximab) do provide specific parameters for holding  
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therapy during a presumable viral upper respiratory infection when the fever is greater than 101 
degrees Fahrenheit (Saag et al., 2008).  
The biologic should continue to be withheld during the full course of antibiotics and until 
full recovery has been achieved. Additionally, if a patient continues to be susceptible to multiple 
infections or is infected with an opportunistic pathogen the biologic therapy should be 
completely discontinued and not re-started (Menter et al., 2008). This was reiterated in the 
American College of Rheumatology 2015 guideline that indicated that biologic treatment 
benefits should outweigh the risk of infection, and should be discontinued in the setting of severe 
or recurrent infections (Singh et al., 2016). 
In order to prevent infections from developing in the individual on biologic therapy the 
primary care provider should ensure that all recommended vaccinations are current. This may 
prevent some illnesses from developing or reduce the severity of symptoms experienced by the 
patient (Weigt, Gregson, Deng, Lynch, & Belpe- Rio, 2011). Prior to starting biologic therapy, it 
is recommended that the patient be given any vaccinations that they would be routinely due for 
based on the United States Center for Disease Control guidelines, as well as screening for 
tuberculosis to ensure that the patient does not have latent or unknown tuberculosis that could 
potentially be re-activated once the immune system is suppressed (Bombardier, 2012).  
The American College of Rheumatology recommends that prior to initiating biologic 
therapy a patient should receive the killed recombinant pneumococcal vaccination, influenza 
vaccination, hepatitis B vaccination series, the human papillomavirus vaccination, and the live 
attenuated herpes zoster vaccination (Singh et al., 2016). The Canadian Rheumatology 
Association has similar recommendations for administration of vaccinations and provides 
guidelines for timing of each vaccination. Live vaccinations should be administered at least two 
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to four weeks prior in initiating biologic therapy, and inactive killed vaccinations can be given 
any time prior to initiation of treatment (Bombardier, 2012).  
Vaccination is important for the patient on biologic therapy as it can prevent contraction 
of disease, and  decrease the severity of symptoms experienced. Observational studies have 
found that individuals with rheumatoid arthritis who take medications like biologics or other 
immune suppressing therapies have fewer symptoms and complications with influenza if 
vaccinated. A study comparing vaccinated versus unvaccinated individuals with rheumatoid 
arthritis found that the unvaccinated group had a higher incidence of acute bronchitis and viral 
respiratory infections over a year-long period (Stojanovich, 2006). Two additional observational 
studies found decrease in hospital admissions and mortality from influenza and pneumonia in 
older adults with rheumatoid arthritis who received the influenza vaccination (Bombardier, 2012). 
Once a patient is on biologic therapy it is not recommended that live vaccinations be 
administered. The use of live vaccinations while on biologic therapy is contraindicated as the 
patient’s immune system is decreased and introducing a live form of a virus or bacteria may 
cause actual disseminated infection. Common live vaccinations include the measles, mumps, 
rubella, nasal influenza mist, varicella, and herpes zoster vaccinations (Bombardier, 2012). 
Inactive vaccinations can be given while a patient is on biologic therapy, but the immune 
response may not be as active, and reduced antibody production may occur. The influenza 
intramuscular vaccine and the pneumococcus vaccination are both inactive vaccinations and are 
recommended to be given routinely to individuals while on biologic treatment (Bombardier, 
2012). 
Based on the recommendations outline above, it would be advisable for the patient in this 
case study to hold his biologic therapy during his acute upper respiratory illness. He was 
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experiencing fevers consistently over the threshold of 101 degrees Fahrenheit, and therefore 
would be classified as having a severe viral infection in the context of using a tumor necrosis 
factor inhibitor. It also would be important for the primary care provider to consider alternatives 
to the common causes of infection, as those on biologics may be at risk for opportunistic 
infections. The primary care provider needs to closely monitor the patient’s condition for 
progression to a more acute bacterial or viral pneumonia, with close follow-up and low threshold 
for obtaining further laboratory work and imaging to ensure there is no advancement of the 
infection. The patient had obtained his annual influenza vaccination, so if he did have influenza 
the severity of his symptoms would likely be decreased. The patient would, however, be a 
candidate for a pneumococcal vaccination, and should receive this once his illness subsides to 
prevent the development of future pneumonia due to his immunocompromised state. 
Learning Points 
• The patient on biologic therapy has a reduced immune response, and is therefore at 
increased risk for common and opportunistic infections (Le Saux, 2012). 
• Biologic therapy should be withheld while a patient has an active severe infection or 
while on antibiotic treatment (Saag et al., 2008). 
• Live vaccinations should be given prior to initiating biologic therapy, and should not 
be given while on biologic therapy (Bombardier, 2012). 
• Killed vaccinations can be given while on biologic therapy, and the influenza and 
pneumococcal vaccinations are highly recommended to reduce incidence and 
severity of potential upper respiratory illness (Bombardier, 2012).  
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